newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech to Participate in a Solve M.E. Signature Event: 'Long COVID: Research, Policy, and Economic Impact' on May 19, 2022

OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral